Ring Therapeutics at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Ring Therapeutics at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Ring Therapeutics Cleveland, Ohio	1 PhD Student
ringtx.com\|LinkedIn Ring Therapeutics develops vector conjugate medicines and modular manufacturing technology for targeted drug development. Presented Vector Conjugate and VectorBricks data at ASGCT (2026-05) › Presented Vector Conjugate and VectorBricks data at ASGCT · 2026-05-14 “highlight significantly increased cargo capacity for the delivery of oligonucleotides using targetable vectors and VectorBricks as a scalable in vitro manufacturing platform” Presented AnelloBricks manufacturing data at ASGCT · 2025-05-13 “announced new data demonstrating successful infectivity and expression of AnelloVectors produced with its AnelloBricks in vitro assembly technology” Source: company newsroom Raised $86.5M (Series C, 2023-03) › $86.5 million Series C funding on March 9, 2023. Lead investors were not stated; named investors included Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Flagship Pioneering, Invus, Kyowa Kirin, Partners Investment, T. Rowe Price-advised funds, and UPMC Enterprises. · 2023-03-09 “raised $86.5 million in Series C funding” Source: funding announcement	Poster Wed Oct 21 2:30 pm Part of Genetic, Genomic, and Epigenomic Resources and Databases Poster Wednesday Session A draft Alzheimer's disease-specific human pangenome reference enhance genetic variant and gene discovery Exhibit & Poster Hall · Board 4015W Collaborators: Cleveland Clinic, Case Western Reserve University Alzheimer’s diseaseHaplotypeSNP analysis/discoveryGenetic variation

Organization

ASHG 2026 Attendance

Ring Therapeutics

Cleveland, Ohio

1 PhD Student

ringtx.com|LinkedIn

Ring Therapeutics develops vector conjugate medicines and modular manufacturing technology for targeted drug development.

Presented Vector Conjugate and VectorBricks data at ASGCT (2026-05)

›

Presented Vector Conjugate and VectorBricks data at ASGCT · 2026-05-14

“highlight significantly increased cargo capacity for the delivery of oligonucleotides using targetable vectors and VectorBricks as a scalable in vitro manufacturing platform”

Presented AnelloBricks manufacturing data at ASGCT · 2025-05-13

“announced new data demonstrating successful infectivity and expression of AnelloVectors produced with its AnelloBricks in vitro assembly technology”

Source: company newsroom

Raised $86.5M (Series C, 2023-03)

›

$86.5 million Series C funding on March 9, 2023. Lead investors were not stated; named investors included Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Flagship Pioneering, Invus, Kyowa Kirin, Partners Investment, T. Rowe Price-advised funds, and UPMC Enterprises. · 2023-03-09

“raised $86.5 million in Series C funding”

Source: funding announcement

Poster

Wed Oct 21
2:30 pm

Part of Genetic, Genomic, and Epigenomic Resources and Databases Poster Wednesday Session

A draft Alzheimer's disease-specific human pangenome reference enhance genetic variant and gene discovery

Exhibit & Poster Hall · Board 4015W

Collaborators: Cleveland Clinic, Case Western Reserve University

Alzheimer’s diseaseHaplotypeSNP analysis/discoveryGenetic variation